Azelastine
Astepro, Dymista (azelastine) is a small molecule pharmaceutical. Azelastine was first approved as Astelin on 1996-11-01. It is used to treat allergic conjunctivitis, allergic rhinitis perennial, and vasomotor rhinitis in the USA. The pharmaceutical is active against histamine H1 receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Astepro (generic drugs available since 2009-04-30, discontinued: Astelin, Optivar)
CombinationsDymista (generic drugs available since 2009-04-30)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Azelastine hydrochloride
Azelastine hydrochloride
+
Fluticasone propionate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
DYMISTA | Mylan | N-202236 RX | 2012-05-01 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
astelin | New Drug Application | 2010-05-18 |
astepro allergy | New Drug Application | 2022-06-27 |
azelastine hydrochloride | ANDA | 2023-06-07 |
dymista | New Drug Application | 2021-04-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
allergic conjunctivitis | EFO_0007141 | D003233 | H10.44 |
allergic rhinitis perennial | EFO_1001417 | D012221 | J30.89 |
vasomotor rhinitis | EFO_0007533 | D012223 | J30.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Azelastine Hydrochloride, Astepro, Mylan Speciality Lp | |||
8071073 | 2028-06-04 | DP | |
8518919 | 2025-11-22 | U-1430, U-3166 | |
9919050 | 2025-11-22 | DP | |
Azelastine Hydrochloride / Fluticasone Propionate, Dymista, Mylan Speciality Lp | |||
8168620 | 2026-02-24 | DP | |
8163723 | 2023-08-29 | U-77, U-81, U-644, U-707, U-1667 | |
9259428 | 2023-06-13 | U-644 | |
9901585 | 2023-06-13 | DP |
ATC Codes
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AC: Antiallergic nasal preparations for topical use, excl. corticosteroids
— R01AC03: Azelastine
— R06: Antihistamines for systemic use
— R06A: Antihistamines for systemic use
— R06AX: Other antihistamines for systemic use in atc
— R06AX19: Azelastine
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01G: Decongestants and antiallergics
— S01GX: Other antiallergics in atc
— S01GX07: Azelastine
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | AZELASTINE |
INN | azelastine |
Description | Azelastine is a phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position. It has a role as a H1-receptor antagonist, an anti-allergic agent, an anti-asthmatic drug, a bronchodilator agent, a platelet aggregation inhibitor and an EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor. It is a member of phthalazines, a tertiary amino compound and a member of monochlorobenzenes. |
Classification | Small molecule |
Drug class | antihistaminics (histamine-H1 receptor antagonists) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1 |
Target
Variants
Clinical Variant
No data
Financial
Dymista - Viatris
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,228 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
14 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more